Differential expression of interleukins IL-13 and IL-15 in normal ovarian tissue and ovarian carcinomas

Gynecologic Oncology

Volumn 92, Issue 3, 2004, Pages 761-768

  Ripley, Daylene ^a   Shoup, Brenda ^a   Majewski, Andrew ^a   Chegini, Nasser ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

Cytokines; Expression; Interleukins; Ovary; Tumors

Indexed keywords

INTERLEUKIN 13; INTERLEUKIN 15; MESSENGER RNA;

ASCITES; CONFERENCE PAPER; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; EPITHELIUM CELL; FEMALE; GRANULOSA CELL; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; INFLAMMATORY CELL; LUTEAL CELL; MAJOR CLINICAL STUDY; MENSTRUAL CYCLE; METASTASIS; OVARY; OVARY CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL;

EID: 1342321836     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ygyno.2003.12.011     Document Type: Conference Paper

References (56)

1. Hensley M.L. Epithelial ovarian cancer. Curr. Treatm. Opt. Oncol. 3:2002;131-141.
2. Matias-Guiu X., Prat J. Molecular pathology of ovarian carcinomas. Virchows Arch. 433:1998;103-111.
3. Gregoire L., Rabah R., Schmelz E.M., Munkarah A., Roberts P.C., Lancaster W.D. Spontaneous malignant transformation of human ovarian surface epithelial cells in vitro. Clin. Cancer Res. 7:2001;4280-4287.
4. Kamura T., Jeon J.D. Lymph node metastasis in a gynecologic malignancy. Yonsei Med. J. 43:2002;783-791.
5. Capo-Chichi C.D., Smith E.R., Yang D.H., Roland I.H., Vanderveer L., Cohen C.et al. Dynamic alterations of the extracellular environment of ovarian surface epithelial cells in premalignant transformation, tumorigenicity, and metastasis. Cancer. 95:2002;1802-1815.
6. Murdoch W.J., McDonnel A.C. Roles of the ovarian surface epithelium in ovulation and carcinogenesis. Reproduction. 123:2002;743-750.
7. Huber J.C., Schneeberger C., Tempfer C.B. Genetic modelling of the estrogen metabolism as a risk factor of hormone-dependent disorders. Maturitas. 42:2002;1-12.
8. Risch H.A. Hormonal etiology of epithelial ovarian cancer, with a hypothesis concerning the role of androgens and progesterone. J. Natl. Cancer Inst. 90:1998;1774-1786.
9. Scully R.E. Hormonally active ovarian tumors. Verh. Dtsch. Ges. Pathol. 81:1997;245-252.
10. Zavadova E., Loercher A., Verstovsek S., Verschraegen C.F., Micksche M., Freedman R.S. The role of macrophages in antitumor defense of patients with ovarian cancer. Hematol. Oncol. Clin. North Am. 13:1999;135-144.
11. Zhang L., Conejo-Garcia J.R., Katsaros D., Gimotty P.A., Massobrio M., Regnani G.et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N. Engl. J. Med. 348:2003;203-213.
12. Westermann A.M., Beijnen J.H., Moolenaar W.H., Rodenhuis S. Growth factors in human ovarian cancer. Cancer Treat. Rev. 23:1997;113-131.
13. Burke F., Relf M., Negus R., Balkwill F. A cytokine profile of normal and malignant ovary. Cytokine. 8:1996;578-585.
14. Milliken D., Scotton C., Raju S., Balkwill F., Wilson J. Analysis of chemokines and chemokine receptor expression in ovarian cancer ascites. Clin. Cancer Res. 8:2002;1108-1114.
15. Herrera C.A., Xu L., Bucana C.D., Silva el V.G., Hess K.R., Gershenson D.M.et al. Expression of metastasis-related genes in human epithelial ovarian tumors. Int. J. Oncol. 20:2002;5-13.
16. Richards J.S., Russell D.L., Ochsner S., Hsieh M., Doyle K.H., Falender A.E.et al. Novel signaling pathways that control ovarian follicular development, ovulation, and luteinization. Recent Prog. Horm. Res. 57:2002;195-220.
17. Fields A.L., Runowicz C.D. Current therapies in ovarian cancer. Cancer Invest. 21:2003;148-156.
18. Berek J.S., Dorigo O., Schultes B., Nicodemus C. Specific keynote: immunological therapy for ovarian cancer. Gynecol. Oncol. 88(1 Pt 2):2003;S105-S109.
19. Auersperg N., Wong A.S., Choi K.C., Kang S.K., Leung P.C. Ovarian surface epithelium: biology, endocrinology, and pathology. Endocr. Rev. 22:2001;255-288.
20. Chomarat P., Bannchereau J. Interleukin-4 and interleukin-13: their similarities and discrepancies. Int. Rev. Immunol. 17:1998;1-52.
21. Waldmann T.A., Tagaya Y. The multifaceted regulation of interleukin-15 expression and the role of this cytokine in NK cell differentiation and host response to intracellular pathogens1. Annu. Rev. Immunol. 17:1999;19-49.
22. Kawakami K., Kawakami M., Joshi B.H., Puri R.K. Interleukin-13 receptor-targeted cancer therapy in an immunodeficient animal model of human head and neck cancer. Cancer Res. 61:2001;6194-6200.
23. Rahaman S.O., Sharma P., Harbor P.C., Aman M.J., Vogelbaum M.A., Haque S.J. IL-13R(alpha)2, a decoy receptor for IL-13 acts as an inhibitor of IL-4-dependent signal transduction in glioblastoma cells. Cancer Res. 62:2002;1103-1109.
24. Bernard J., Treton D., Vermot-Desroches C., Boden C., Horellou P., Angevin E.et al. Expression of interleukin 13 receptor in glioma and renal cell carcinoma: IL13Ralpha2 as a decoy receptor for IL13. Lab. Invest. 81:2001;1223-1231.
25. Skinnider B.F., Kapp U., Mak T.W. Interleukin 13: a growth factor in Hodgkin lymphoma. Int. Arch. Allergy Immunol. 126:2001;267-276.
26. Fiumara P., Cabanillas F., Younes A. Interleukin-13 levels in serum from patients with Hodgkin disease and healthy volunteers. Blood. 98:2001;2877-2878.
27. Denizot Y., Turlure P., Bordessoule D., Trimoreau F., Praloran V. Serum IL-10 and IL-13 concentrations in patients with haematological malignancies. Cytokine. 11:1999;634-635.
28. Doucet C., Jasmin C., Azzarone B. Unusual interleukin-4 and -13 signaling in human normal and tumor lung fibroblasts. Oncogene. 19:2000;5898-5905.
29. Kawakami K., Kawakami M., Snoy P.J., Husain S.R., Puri R.K. In vivo overexpression of IL-13 receptor alpha2 chain inhibits tumorigenicity of human breast and pancreatic tumors in immunodeficient mice. J. Exp. Med. 194:2001;1743-1754.
30. Husain S.R., Puri R.K. Interleukin-13 fusion cytotoxin as a potent targeted agent for AIDS-Kaposi's sarcoma xenograft. Blood. 95:2000;3506-3513.
31. Kanai T., Watanabe M., Hayashi A., Nakazawa A., Yajima T., Okazawa A.et al. Regulatory effect of interleukin-4 and interleukin-13 on colon cancer cell adhesion. Br. J. Cancer. 82:2000;1717-1723.
32. Woerly G., Roger N., Loiseau S., Capron M. Expression of Th1 and Th2 immunoregulatory cytokines by human eosinophils. Int. Arch. Allergy Immunol. 118:1999;95-97.
33. Gabay C., Porter B., Guenette D., Billir B., Arend W.P. Interleukin-4 (IL-4) and IL-13 enhance the effect of IL-1beta on production of IL-1 receptor antagonist by human primary hepatocytes and hepatoma HepG2 cells: differential effect on C-reactive protein production. Blood. 93:1999;1299-1307.
34. Gingras S., Cote S., Simard J. Multiple signal transduction pathways mediate interleukin-4-induced 3beta-hydroxysteroid dehydrogenase/Delta5-Delta4 isomerase in normal and tumoral target tissues. J. Steroid Biochem. Mol. Biol. 76:2001;213-225.
35. Simard J., Gingras S. Crucial role of cytokines in sex steroid formation in normal and tumoral tissues. Mol. Cell. Endocrinol. 171:2001;25-40.
36. Marks-Konczalik J., Dubois S., Losi J.M., Sabzevari H., Yamada N., Feigenbaum L.et al. IL-2-induced activation-induced cell death is inhibited in IL-15 transgenic mice. Proc. Natl. Acad. Sci. U. S. A. 97:2000;11445-11450.
37. Musso T., Calosso L., Zucca M., Millesimo M., Ravarino D., Giovarelli M.et al. Human monocytes constitutively express membrane-bound, biologically active, and interferon-gamma-upregulated interleukin-15. Blood. 93:1999;3531-3539.
38. Fehniger T.A., Caligiuri M.A. Interleukin 15: biology and relevance to human disease. Blood. 97:2001;14-32.
39. Kuniyasu H., Oue N., Nakae D., Tsutsumi M., Denda A., Tsujiuchi T.et al. Interleukin-15 expression is associated with malignant potential in colon cancer cells. Pathobiology. 69:2001;86-95.
40. Handisurya A., Steiner G.E., Stix U., Ecker R.C., Pfaffeneder-Mantai S., Langer D.et al. Differential expression of interleukin-15, a pro-inflammatory cytokine and T-cell growth factor, and its receptor in human prostate. Prostate. 49:2001;251-262.
41. Hazelbag S., Fleuren G.J., Baelde J.J., Schuuring E., Kenter G.G., Gorter A. Cytokine profile of cervical cancer cells. Gynecol. Oncol. 83:2001;235-243.
42. Suzuki K., Nakazato H., Matsui H., Hasumi M., Shibata Y., Ito K.et al. NK cell-mediated anti-tumor immune response to human prostate cancer cell, PC-3: immunogene therapy using a highly secretable form of interleukin-15 gene transfer. J. Leukoc. Biol. 69:2001;531-537.
43. Takeuchi E., Yanagawa H., Suzuki Y., Shinkawa K., Bando H., Sone S. Interleukin (IL-)15 has less activity than IL-2 to promote type 2 cytokine predominance in tumour-associated mononuclear cells from lung cancer patients. Cytokine. 13:2001;119-123.
44. Chegini N., Ma C., Roberts M., Williams R.S., Ripps B.A. Differential expression of interleukins (IL) IL-13 and IL-15 throughout the menstrual cycle in endometrium of normal fertile women and women with recurrent spontaneous abortion. J. Reprod. Immunol. 56:2002;93-110.
45. Chegini N., Roberts M., Ripps B. Differential expression of interleukins (IL)-13 and IL-15 in ectopic and eutopic endometrium of women with endometriosis and normal fertile women. Am. J. Reprod. Immunol. 49:2003;75-83.
46. Nash M.A., Ferrandina G., Gordinier M., Loercher A., Freedman R.S. The role of cytokines in both the normal and malignant ovary. Endocr. Relat. Cancer. 6:1999;93-107.
47. Waldmann T.A., Dubois S., Tagaya Y. Contrasting roles of IL-2 and IL-15 in the life and death of lymphocytes: implications for immunotherapy. Immunity. 14:2001;105-110.
48. Zheng T., Zhu Z., Wang Z., Homer R.J., Ma B., Riese R.J. Jr.et al. Inducible targeting of IL-13 to the adult lung causes matrix metalloproteinase- and cathepsin-dependent emphysema. J. Clin. Invest. 106:2000;1081-1093.
49. Constantinescu C.S., Grygar C., Kappos L., Leppert D. Interleukin 15 stimulates production of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 by human peripheral blood mononuclear cells. Cytokine. 13:2001;244-247.
50. Gallinelli A., Ciaccio I., Giannella L., Salvatori M., Marsella T., Volpe A. Correlations between concentrations of interleukin-12 and interleukin-13 and lymphocyte subsets in the follicular fluid of women with and without polycystic ovary syndrome. Fertil. Steril. 79:2003;1365-1372.
51. Odukoya O.A., Ajjan R., Lim K., Watson P.F., Weetman A.P., Cooke I.D. The pattern of cytokine mRNA expression in ovarian endometriomata. Mol. Hum. Reprod. 3:1997;393-397.
52. Mehrotra R. Interleukin 13 is secreted by human head and neck tumours and does not modulate their growth in vitro. Indian J. Exp. Biol. 36:1998;805-807.
53. Obiri N.I., Husain S.R., Debinski W., Puri R.K. Interleukin 13 inhibits growth of human renal cell carcinoma cells independently of the p140 interleukin 4 receptor chain. Clin. Cancer Res. 2:1996;1743-1749.
54. Seppanen M., Vihko K.K. Activation of transcription factor NF-kappaB by growth inhibitory cytokines in vulvar carcinoma cells. Immunol. Lett. 74:2000;103-109.
55. Seppanen M., Henttinen T., Lin L., Punnonen J., Grenman S., Punnonen R. et al. Inhibitory effects of cytokines on ovarian and endometrial carcinoma cells in vitro with special reference to induction of specific transcriptional regulators. Oncol. Res. 10:1998;575-589.
56. Kawakami K., Husain S.R., Bright R.K., Puri R.K. Gene transfer of interleukin 13 receptor alpha2 chain dramatically enhances the antitumor effect of IL-13 receptor-targeted cytotoxin in human prostate cancer xenografts. Cancer Gene Ther. 8:2001;861-868.